Akebia (AKBA) Therapeutics announced that it has commenced an underwritten public offering. All shares are being offered by Akebia. Leerink Partners and Piper Sandler & Co. are acting as joint bookrunning managers for the offering.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKBA:
- Akebia Therapeutics’ Strong Market Performance and Strategic Initiatives Drive Buy Rating
- Akebia price target raised to $6 from $4 at Piper Sandler
- Akebia Therapeutics Faces Global Regulatory Challenges Amid Brexit and EU Changes
- Akebia Therapeutics Reports Progress in Vafseo Launch
- Akebia Therapeutics’ Earnings Call Highlights Vafseo Success
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue